DDInter1380 DDInter178
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon alfa-n1
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1